Vaxcyte, Inc. with ticker code (PCVX) now have 7 analysts in total covering the stock. The consensus rating is pointing to ‘strong_buy’. The target price High/Low ranges between 72 and 58 calculating the average target price we see $66.29. Given that the stocks previous close was at $49.48 and the analysts are correct then we can expect a percentage increase in value of 34.0%. The 50 day moving average now sits at $42.77 and the 200 day MA is $38.69. The market capitalization for the company is 4.73B. The stock price is currently at: 50.5 USD
The potential market cap would be $6,339,876,567 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of – and a -23.41% return on assets.
Vaxcyte Inc. is a clinical-stage vaccine company. The Company develops conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its synthetic techniques include advanced chemistry and the XpressCF cell-free protein synthesis platform, licensed from Sutro Biopharma, Inc., or Sutro Biopharma. Its pipeline includes Pneumococcal conjugate vaccine (PCV), VAX-A1, VAX-PG and VAX-GI. Its lead vaccine candidate, VAX-24, is a 24-valent investigational PCV being developed for the prevention of invasive pneumococcal disease (IPD). Its second PCV candidate, VAX-31, is designed to prevent IPD. population. VAX- 24 is intended to improve upon the standard-of-care PCV vaccines for both children and adults. VAX-A1 is a conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus or Group A Strep. VAX-PG is a protein vaccine candidate targeting the keystone pathogen responsible for periodontitis. VAX-GI is a vaccine program designed to prevent Shigella.
